Brandstetter L, Grau A, Heuschmann P, Muller-Reiter M, Salmen J, Stork S
BMC Cancer. 2025; 25(1):125.
PMID: 39844089
PMC: 11756166.
DOI: 10.1186/s12885-025-13548-8.
Rehman H, Yousaf N, Hina S, Nadeem T, Ansari M, Chaudry A
Toxicol Res (Camb). 2024; 13(6):tfae179.
PMID: 39507591
PMC: 11535352.
DOI: 10.1093/toxres/tfae179.
Yu L, Zhang C, Liu L, Chen X
Pharmacogenomics. 2024; 25(10-11):461-468.
PMID: 39392082
PMC: 11492633.
DOI: 10.1080/14622416.2024.2404819.
Wang K, Shen L, Chen Y, Tang Z
Biomed Eng Online. 2024; 23(1):81.
PMID: 39135013
PMC: 11318265.
DOI: 10.1186/s12938-024-01274-4.
Tailor N, Singh Grewal A, Deswal G, Dhingra A
Anticancer Agents Med Chem. 2024; 24(19):1396-1406.
PMID: 39113300
DOI: 10.2174/0118715206312324240805075050.
Leveraging preclinical models of metastatic breast cancer.
Pedroza D, Gao Y, Zhang X, Rosen J
Biochim Biophys Acta Rev Cancer. 2024; 1879(5):189163.
PMID: 39084494
PMC: 11390310.
DOI: 10.1016/j.bbcan.2024.189163.
DNA damage targeted therapy for advanced breast cancer.
Patel V, Casimiro S, Abreu C, Barroso T, de Sousa R, Torres S
Explor Target Antitumor Ther. 2024; 5(3):678-698.
PMID: 38966174
PMC: 11220312.
DOI: 10.37349/etat.2024.00241.
Development and validation of AI models using LR and LightGBM for predicting distant metastasis in breast cancer: a dual-center study.
Zhang W, Tan Y, Huang Z, Tan Q, Zhang Y, Chen B
Front Oncol. 2024; 14:1409273.
PMID: 38947897
PMC: 11211559.
DOI: 10.3389/fonc.2024.1409273.
Radiation-induced dermatitis among breast cancer patients undergoing adjuvant radiotherapy in Ghana.
Kyei K, Anim-Sampong S, Akoe E, Daniels J, Obeng-Mensah T, Antwi W
Transl Oncol. 2024; 46:102028.
PMID: 38861854
PMC: 11209633.
DOI: 10.1016/j.tranon.2024.102028.
Joint EANM-SNMMI guideline on the role of 2-[F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).
Vaz S, Pilkington Woll J, Cardoso F, Groheux D, Cook G, Ulaner G
Eur J Nucl Med Mol Imaging. 2024; 51(9):2706-2732.
PMID: 38740576
PMC: 11224102.
DOI: 10.1007/s00259-024-06696-9.
Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study.
Zhang S, Yang H, Xu Y, Wang S
Breast Cancer Res Treat. 2024; 206(3):637-651.
PMID: 38727889
DOI: 10.1007/s10549-024-07340-8.
Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim Y, Chung Y, Park E, Lee S, Lee J
Sci Rep. 2024; 14(1):7992.
PMID: 38580676
PMC: 10997762.
DOI: 10.1038/s41598-024-57515-y.
Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review.
Brandstetter L, Jiru-Hillmann S, Stork S, Heuschmann P, Wockel A, Reese J
Patient. 2024; 17(4):349-362.
PMID: 38451419
PMC: 11190003.
DOI: 10.1007/s40271-024-00679-6.
Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases.
Zhang Q, Lan X, Huang J, Xie X, Chen L, Song L
Technol Cancer Res Treat. 2024; 23:15330338231206986.
PMID: 38233376
PMC: 10798105.
DOI: 10.1177/15330338231206986.
Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review.
Yeo H, Liew A, Chan S, Anwar M, Han C, Marra C
Patient Prefer Adherence. 2023; 17:2679-2706.
PMID: 37927344
PMC: 10625390.
DOI: 10.2147/PPA.S432821.
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Ring A, Karuturi M, Smyth E, Lokhandwala T, Sheffield K, Willey J
Drugs Real World Outcomes. 2023; 10(4):589-603.
PMID: 37775689
PMC: 10730497.
DOI: 10.1007/s40801-023-00391-1.
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators.
Song X, Wang P, Feng R, Chetry M, Li E, Wu X
Clin Transl Oncol. 2023; 26(2):389-397.
PMID: 37713046
DOI: 10.1007/s12094-023-03316-0.
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J
BMC Cancer. 2023; 23(1):816.
PMID: 37653504
PMC: 10469949.
DOI: 10.1186/s12885-023-11322-2.
A photothermal driven chemotherapy for the treatment of metastatic melanoma.
Bhatt H, Diwan R, Borrego E, Martinez Perez C, Varela-Ramirez A, Kumar R
J Control Release. 2023; 361:314-333.
PMID: 37562554
PMC: 10787601.
DOI: 10.1016/j.jconrel.2023.08.005.
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Kim J, Shin J, Ahn J, Park Y, Im Y
Cancers (Basel). 2023; 15(13).
PMID: 37444541
PMC: 10341332.
DOI: 10.3390/cancers15133431.
